91474-98-5

Upstream product

• 115441-65-1 methyl N-Cbz-N,O-dimethyl-L-tyrosyl-L-alaninate 
• 135103-27-4 C₁₆H₂₃NO₅*C₁₂H₂₃N 
• 73584-84-6 (S)-2-(tert-butoxycarbonyl(methyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 115441-64-0 methyl N-Cbz-N-methyl-L-tyrosyl-L-alaninate 
• 86099-14-1 (2S)-3-(4-hydroxyphenyl)-2-(methyl{[(phenylmethyl)oxy]carbonyl}amino)propanoic acid 
• 91474-97-4 methyl O,N-dimethyl-N-boc-L-tyr-L-alaninate 

Downstream Products

• 91475-00-2 methyl N-boc-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91475-01-3 methyl N-boc-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 112196-84-6 BOC-D-Ala-L-Ala-NMe-L-Tyr(OMe)-L-Ala-OH 
• 112219-54-2 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-Amino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid pentafluorophenyl ester; compound with trifluoro-acetic acid 
• 112196-67-5 C₄₆H₅₁F₅N₆O₁₀*C₂HF₃O₂ 
• 112196-48-2 cyclo-(D-Ala-Ala-N-Me-Tyr(OMe)-Ala) 
• 112196-46-0 Cyclo-(D-Ala-Ala-N-Me-Tyr(OCH₃)-Ala-N-Me-Gly-N-Me-Gly) 
• 112196-47-1 (12R,15S,18S,21S)-18-(4-Methoxy-benzyl)-12,15,17,21,23-pentamethyl-2-oxa-11,14,17,20,23-pentaaza-tricyclo[24.2.2.1^3,7]hentriaconta-1⁽²⁹⁾,3⁽³¹⁾,4,6,26⁽³⁰⁾,27-hexaene-10,13,16,19,22-pentaone 
• 112219-52-0 Boc-D-Ala-Ala-N-Me-Tyr(OMe)-Ala-N-Me-Gly-N-Me-Gly-OH 
• 112196-52-8 Boc-D-Ala-Ala-N-Me-Tyr(OMe)-N-Me-Gly-N-Me-Gly-OMe 
• 112196-81-3 BOC-D-Ala-L-Ala-NMe-L-Tyr(OMe)-L-Ala-OC₆F₅ 
• 112196-75-5 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid 
• 112196-74-4 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid methyl ester 
• 112196-80-2 (S)-2-[(S)-2-{[(S)-2-((R)-2-Amino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionic acid; compound with trifluoro-acetic acid 

Relevant academic research and scientific papers

BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF

The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvar

Structures of cytotoxic bicyclic hexapeptides, RA-XIX, -XX, -XXI, and -XXII, from Rubia cordifolia L.

Novel bicyclic hexapeptides, RA-XIX, -XX, -XXI, and -XXII, were isolated from the roots of Rubia cordifolia L. The structures of RA-XIX and RA-XX were established by semisynthesis from a cycloisodityrosine, derived from previously reported RA-VII, and those of RA-XXI and RA-XXII by chemical correlation with RA-XX and previously reported RA-VIII, respectively. The IC50 values of these new peptides against P-388 leukemia cells were 0.013-0.63 μg/mL.

Synthesis of [Gly-1]RA-VII, [Gly-2]RA-VII, and [Gly-4]RA-VII. Glycine-Containing Analogues of RA-VII, an Antitumor Bicyclic Hexapeptide from Rubia Plants

Three analogues of RA-VII (1), an antitumor bicyclic hexapeptide from Rubia plants, were synthesized. Three analogues, [Gly-1]RA-VII (4), [Gly-2]RA-VII (5), and [Gly-4]RA-VII (6), in which one of the three alanine residues in 1 was replaced by a glycine r

Isolation, structural elucidation, and synthesis of RA-XVII, a novel bicyclic hexapeptide from Rubia cordifolia, and the effect of side chain at residue 1 upon the conformation and cytotoxic activity

A novel antitumor bicyclic hexapeptide RA-XVII was isolated from the roots of Rubia cordifolia. By spectral studies and synthetic approach, its structure was determined to be [D-2-aminobutyric acid-1]deoxybouvardin. Studies on the effect of side chain at

SYNTHESIS OF CYCLO-N-METHYL-L-TYR-N-METHYL-L-TYR-D-ALA-L-ALA-O,N-DIMETHYL-L-TYR-L-ALA, A CYCLIC HEXAPEPTIDE RELATED TO THE ANTITUMOR AGENT DEOXYBOUVARDIN

A synthesis of the title cyclic hexapeptide is described.Its lack of antitumor activity shows that the 14-membered ring of deoxybouvardin is needed for activity.Efforts to oxidatively its phenolic groups failed to give deoxybouvardin.